Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer

de Blanck, Steen Riisgaard ; Rydhög, Jonas Scherman ; Larsen, Klaus Richter ; Clementsen, Paul Frost ; Josipovic, Mirjana ; Aznar, Marianne Camille ; af Rosenschöld, Per Munck LU orcid ; Jølck, Rasmus Irming ; Specht, Lena and Andresen, Thomas Lars , et al. (2018) In Clinical and Translational Radiation Oncology 13. p.24-28
Abstract

Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.

Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
subject
keywords
EBUS, Endoscopic ultrasound, Image-guided radiotherapy, Liquid fiducial marker, NSCLC
in
Clinical and Translational Radiation Oncology
volume
13
pages
24 - 28
publisher
Elsevier
external identifiers
  • scopus:85069701708
ISSN
2405-6308
DOI
10.1016/j.ctro.2018.07.004
language
English
LU publication?
no
additional info
Publisher Copyright: © 2018 The Authors
id
11d4f4c9-a26b-4a93-8652-61569e35ab8e
date added to LUP
2023-07-19 17:13:37
date last changed
2023-07-31 11:12:02
@article{11d4f4c9-a26b-4a93-8652-61569e35ab8e,
  abstract     = {{<p>Safety and clinical feasibility of injecting a novel liquid fiducial marker for use in image guided radiotherapy in 15 patients with non-small cell lung cancer are reported. No major safety or toxicity issues were encountered. Markers present at start of radiotherapy remained visible in cone beam computed tomography and fluoroscopy images throughout the treatment course and on computed tomography images during follow-up (0–38 months). Marker volume reduction was seen until 9 months after treatment, after which no further marker breakdown was found. No post-treatment migration or marker related complications were found.</p>}},
  author       = {{de Blanck, Steen Riisgaard and Rydhög, Jonas Scherman and Larsen, Klaus Richter and Clementsen, Paul Frost and Josipovic, Mirjana and Aznar, Marianne Camille and af Rosenschöld, Per Munck and Jølck, Rasmus Irming and Specht, Lena and Andresen, Thomas Lars and Persson, Gitte Fredberg}},
  issn         = {{2405-6308}},
  keywords     = {{EBUS; Endoscopic ultrasound; Image-guided radiotherapy; Liquid fiducial marker; NSCLC}},
  language     = {{eng}},
  pages        = {{24--28}},
  publisher    = {{Elsevier}},
  series       = {{Clinical and Translational Radiation Oncology}},
  title        = {{Long term safety and visibility of a novel liquid fiducial marker for use in image guided radiotherapy of non-small cell lung cancer}},
  url          = {{http://dx.doi.org/10.1016/j.ctro.2018.07.004}},
  doi          = {{10.1016/j.ctro.2018.07.004}},
  volume       = {{13}},
  year         = {{2018}},
}